Scienture Expands Arbli Payor Coverage, Adds 12.5M Covered Lives
Event summary
- Scienture added ~12.5M covered lives through expanded payor coverage for Arbli™, including Medicare Part D and commercial plans.
- Arbli™ is the first FDA-approved oral liquid formulation of losartan, targeting pediatric, geriatric, and other patients with swallowing difficulties.
- The company is strengthening its commercial infrastructure with broader pharmacy access and new channel partnerships.
- Arbli™ addresses a $219M U.S. losartan market with ~72M prescriptions annually (IQVIA MAT Apr 2026).
- Scienture aims to capture a portion of the market with its ready-to-use oral liquid formulation.
The big picture
Scienture's expansion of Arbli™'s payor coverage and commercial access positions the company to capture a share of the $219M losartan market. The strategic move aligns with broader industry trends toward patient-centric formulations and improved access to specialty pharmaceuticals. With ~72M losartan prescriptions annually, Scienture aims to differentiate Arbli™ through convenience and consistency, addressing unmet needs in pediatric and geriatric populations.
What we're watching
- Market Penetration
- Whether Scienture can sustain prescription growth by leveraging expanded payor coverage and pharmacy access.
- Competitive Dynamics
- How Arbli™ will compete against compounded losartan formulations and other hypertension treatments.
- Regulatory Compliance
- The impact of FDA and other regulatory requirements on Arbli™'s long-term commercialization strategy.
Related topics